| Ann Keong Ju Jay, MD | |
|
3800 Reservoir Rd Nw, Georgetown University Hospital - Dept. Of Radiology, Washington, DC 20007-2113 | |
| (202) 444-3006 | |
| Not Available |
| Full Name | Ann Keong Ju Jay |
|---|---|
| Gender | Female |
| Speciality | Diagnostic Radiology |
| Experience | 23 Years |
| Location | 3800 Reservoir Rd Nw, Washington, District Of Columbia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235288929 | NPI | - | NPPES |
| P00894801 | Other | DC | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085N0700X | Radiology - Neuroradiology | MT188570 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Medstar Georgetown University Hospital | Washington, DC | Hospital |
| Adventhealth Orlando | Orlando, FL | Hospital |
| Medstar Montgomery Medical Center | Olney, MD | Hospital |
| Adventhealth Daytona Beach | Daytona beach, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Florida Hospital Medical Group Inc | 0042383200 | 218 |
| Florida Radiology Imaging At Lake Mary Llc | 1254311137 | 170 |
| Medstar Medical Group Radiology Llc | 1557589157 | 161 |
| Physician Imaging Of Washington Hospital Center Llc | 6204910292 | 81 |
| Medstar Medical Group - Southern Maryland Llc | 1355667056 | 195 |
| Medstar Medical Group Radiology Llc | 1557589157 | 161 |
| Physician Imaging Of Washington Hospital Center Llc | 6204910292 | 81 |
| Florida Radiology Imaging At Lake Mary Llc | 1254311137 | 170 |
News Archive
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer, today announced the pricing of its initial public offering of 14,300,000 shares of its common stock at $7.00 per share, before underwriting discounts and commissions. All of the shares in the offering are being sold by Merrimack.
Insights into how cells move through the body could lead to innovative techniques to stop cancer cells from spreading and causing secondary tumours, according to new UCL research.
Nurses at Northside Medical Center will conduct informational picketing in front of the hospital on Saturday from 11 a.m. to 1:30 p.m., including some who will wear gags to demonstrate their concerns that management proposals in current contract talks could limit their ability to speak out for patient safety and quality care.
Baxter Healthcare Corporation has announced the presentation of findings from the ADAPT (Analysis of Data from ADVATE Prospective Trials) study program database showing a statistically significant relationship between the duration of time spent with factor VIII blood levels below one international unit per deciliter (1 IU/dL, one percent of normal factor VIII level) and an increase in the annual bleed rate in people with hemophilia A.
In a new UCSF study of more than 2 million mammogram screenings performed on nearly 700,000 women in the United States, scientists for the first time show a direct link between reduced hormone therapy and declines in ductal carcinoma in situ (DCIS) as well as invasive breast cancer. The researchers saw such a striking decrease, they believe they also have uncovered indirect evidence that hormones promote breast tumor growth.
› Verified 7 days ago
| Entity Name | Mgmc Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891797148 PECOS PAC ID: 9537073119 Enrollment ID: O20031220000056 |
News Archive
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer, today announced the pricing of its initial public offering of 14,300,000 shares of its common stock at $7.00 per share, before underwriting discounts and commissions. All of the shares in the offering are being sold by Merrimack.
Insights into how cells move through the body could lead to innovative techniques to stop cancer cells from spreading and causing secondary tumours, according to new UCL research.
Nurses at Northside Medical Center will conduct informational picketing in front of the hospital on Saturday from 11 a.m. to 1:30 p.m., including some who will wear gags to demonstrate their concerns that management proposals in current contract talks could limit their ability to speak out for patient safety and quality care.
Baxter Healthcare Corporation has announced the presentation of findings from the ADAPT (Analysis of Data from ADVATE Prospective Trials) study program database showing a statistically significant relationship between the duration of time spent with factor VIII blood levels below one international unit per deciliter (1 IU/dL, one percent of normal factor VIII level) and an increase in the annual bleed rate in people with hemophilia A.
In a new UCSF study of more than 2 million mammogram screenings performed on nearly 700,000 women in the United States, scientists for the first time show a direct link between reduced hormone therapy and declines in ductal carcinoma in situ (DCIS) as well as invasive breast cancer. The researchers saw such a striking decrease, they believe they also have uncovered indirect evidence that hormones promote breast tumor growth.
› Verified 7 days ago
| Entity Name | Physician Imaging Of Washington Hospital Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831385871 PECOS PAC ID: 6204910292 Enrollment ID: O20080229000143 |
News Archive
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer, today announced the pricing of its initial public offering of 14,300,000 shares of its common stock at $7.00 per share, before underwriting discounts and commissions. All of the shares in the offering are being sold by Merrimack.
Insights into how cells move through the body could lead to innovative techniques to stop cancer cells from spreading and causing secondary tumours, according to new UCL research.
Nurses at Northside Medical Center will conduct informational picketing in front of the hospital on Saturday from 11 a.m. to 1:30 p.m., including some who will wear gags to demonstrate their concerns that management proposals in current contract talks could limit their ability to speak out for patient safety and quality care.
Baxter Healthcare Corporation has announced the presentation of findings from the ADAPT (Analysis of Data from ADVATE Prospective Trials) study program database showing a statistically significant relationship between the duration of time spent with factor VIII blood levels below one international unit per deciliter (1 IU/dL, one percent of normal factor VIII level) and an increase in the annual bleed rate in people with hemophilia A.
In a new UCSF study of more than 2 million mammogram screenings performed on nearly 700,000 women in the United States, scientists for the first time show a direct link between reduced hormone therapy and declines in ductal carcinoma in situ (DCIS) as well as invasive breast cancer. The researchers saw such a striking decrease, they believe they also have uncovered indirect evidence that hormones promote breast tumor growth.
› Verified 7 days ago
| Entity Name | Medstar Medical Group Radiology Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326450156 PECOS PAC ID: 1557589157 Enrollment ID: O20140826000263 |
News Archive
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer, today announced the pricing of its initial public offering of 14,300,000 shares of its common stock at $7.00 per share, before underwriting discounts and commissions. All of the shares in the offering are being sold by Merrimack.
Insights into how cells move through the body could lead to innovative techniques to stop cancer cells from spreading and causing secondary tumours, according to new UCL research.
Nurses at Northside Medical Center will conduct informational picketing in front of the hospital on Saturday from 11 a.m. to 1:30 p.m., including some who will wear gags to demonstrate their concerns that management proposals in current contract talks could limit their ability to speak out for patient safety and quality care.
Baxter Healthcare Corporation has announced the presentation of findings from the ADAPT (Analysis of Data from ADVATE Prospective Trials) study program database showing a statistically significant relationship between the duration of time spent with factor VIII blood levels below one international unit per deciliter (1 IU/dL, one percent of normal factor VIII level) and an increase in the annual bleed rate in people with hemophilia A.
In a new UCSF study of more than 2 million mammogram screenings performed on nearly 700,000 women in the United States, scientists for the first time show a direct link between reduced hormone therapy and declines in ductal carcinoma in situ (DCIS) as well as invasive breast cancer. The researchers saw such a striking decrease, they believe they also have uncovered indirect evidence that hormones promote breast tumor growth.
› Verified 7 days ago
| Entity Name | Florida Radiology Imaging At Lake Mary Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740256494 PECOS PAC ID: 1254311137 Enrollment ID: O20220626000028 |
News Archive
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer, today announced the pricing of its initial public offering of 14,300,000 shares of its common stock at $7.00 per share, before underwriting discounts and commissions. All of the shares in the offering are being sold by Merrimack.
Insights into how cells move through the body could lead to innovative techniques to stop cancer cells from spreading and causing secondary tumours, according to new UCL research.
Nurses at Northside Medical Center will conduct informational picketing in front of the hospital on Saturday from 11 a.m. to 1:30 p.m., including some who will wear gags to demonstrate their concerns that management proposals in current contract talks could limit their ability to speak out for patient safety and quality care.
Baxter Healthcare Corporation has announced the presentation of findings from the ADAPT (Analysis of Data from ADVATE Prospective Trials) study program database showing a statistically significant relationship between the duration of time spent with factor VIII blood levels below one international unit per deciliter (1 IU/dL, one percent of normal factor VIII level) and an increase in the annual bleed rate in people with hemophilia A.
In a new UCSF study of more than 2 million mammogram screenings performed on nearly 700,000 women in the United States, scientists for the first time show a direct link between reduced hormone therapy and declines in ductal carcinoma in situ (DCIS) as well as invasive breast cancer. The researchers saw such a striking decrease, they believe they also have uncovered indirect evidence that hormones promote breast tumor growth.
› Verified 7 days ago
| Entity Name | Florida Hospital Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073785044 PECOS PAC ID: 0042383200 Enrollment ID: O20220719001746 |
News Archive
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer, today announced the pricing of its initial public offering of 14,300,000 shares of its common stock at $7.00 per share, before underwriting discounts and commissions. All of the shares in the offering are being sold by Merrimack.
Insights into how cells move through the body could lead to innovative techniques to stop cancer cells from spreading and causing secondary tumours, according to new UCL research.
Nurses at Northside Medical Center will conduct informational picketing in front of the hospital on Saturday from 11 a.m. to 1:30 p.m., including some who will wear gags to demonstrate their concerns that management proposals in current contract talks could limit their ability to speak out for patient safety and quality care.
Baxter Healthcare Corporation has announced the presentation of findings from the ADAPT (Analysis of Data from ADVATE Prospective Trials) study program database showing a statistically significant relationship between the duration of time spent with factor VIII blood levels below one international unit per deciliter (1 IU/dL, one percent of normal factor VIII level) and an increase in the annual bleed rate in people with hemophilia A.
In a new UCSF study of more than 2 million mammogram screenings performed on nearly 700,000 women in the United States, scientists for the first time show a direct link between reduced hormone therapy and declines in ductal carcinoma in situ (DCIS) as well as invasive breast cancer. The researchers saw such a striking decrease, they believe they also have uncovered indirect evidence that hormones promote breast tumor growth.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ann Keong Ju Jay, MD Po Box 418283, Boston, MA 02241-8283 Ph: (703) 558-1544 | Ann Keong Ju Jay, MD 3800 Reservoir Rd Nw, Georgetown University Hospital - Dept. Of Radiology, Washington, DC 20007-2113 Ph: (202) 444-3006 |
News Archive
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer, today announced the pricing of its initial public offering of 14,300,000 shares of its common stock at $7.00 per share, before underwriting discounts and commissions. All of the shares in the offering are being sold by Merrimack.
Insights into how cells move through the body could lead to innovative techniques to stop cancer cells from spreading and causing secondary tumours, according to new UCL research.
Nurses at Northside Medical Center will conduct informational picketing in front of the hospital on Saturday from 11 a.m. to 1:30 p.m., including some who will wear gags to demonstrate their concerns that management proposals in current contract talks could limit their ability to speak out for patient safety and quality care.
Baxter Healthcare Corporation has announced the presentation of findings from the ADAPT (Analysis of Data from ADVATE Prospective Trials) study program database showing a statistically significant relationship between the duration of time spent with factor VIII blood levels below one international unit per deciliter (1 IU/dL, one percent of normal factor VIII level) and an increase in the annual bleed rate in people with hemophilia A.
In a new UCSF study of more than 2 million mammogram screenings performed on nearly 700,000 women in the United States, scientists for the first time show a direct link between reduced hormone therapy and declines in ductal carcinoma in situ (DCIS) as well as invasive breast cancer. The researchers saw such a striking decrease, they believe they also have uncovered indirect evidence that hormones promote breast tumor growth.
› Verified 7 days ago
Kimberly Smith, Radiology Medicare: Accepting Medicare Assignments Practice Location: 110 Irving St Nw, Washington, DC 20010 Phone: 301-902-1073 | |
Dr. Michael B Shvarts, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 110 Irving St Nw, Washington, DC 20010 Phone: 202-877-7000 | |
Joel Bowers, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 1150 Varnum St Ne, Washington, DC 20017 Phone: 202-269-7000 | |
Krista Lyn Mcfarren, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 3301 New Mexico Ave Nw, Suite 102, Washington, DC 20016 Phone: 202-966-0606 Fax: 202-244-6757 | |
Ranjith Vellody, MD Radiology Medicare: Medicare Enrolled Practice Location: 111 Michigan Ave Nw, Washington, DC 20010 Phone: 202-476-5000 | |
Aaron Conard, Radiology Medicare: Not Enrolled in Medicare Practice Location: 5255 Loughboro Rd Nw, Washington, DC 20016 Phone: 240-366-7325 | |
Dr. Estelle Cooke-sampson, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 2041 Georgia Ave Nw Ste 6101, Washington, DC 20060 Phone: 202-865-6679 Fax: 202-865-3138 |